First human test for new immune drug begins
NCT ID NCT06935266
Summary
This early-stage study aimed to check the safety and tolerability of a new immunoglobulin treatment called TAK-881 in healthy adults. The trial involved 64 healthy volunteers who received the drug under the skin to see how their bodies handled it. Researchers compared two different dosing schedules to find the best way to give the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion
Tempe, Arizona, 85283, United States
Conditions
Explore the condition pages connected to this study.